{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:51:45Z","timestamp":1780469505315,"version":"3.54.1"},"reference-count":64,"publisher":"Medwave Estudios Limitada","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medwave"],"DOI":"10.5867\/medwave.2020.03.7873","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T14:23:14Z","timestamp":1588256594000},"page":"e7873-e7873","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic model of the adaptive changes from hypertensive cardiopathy: from mild diastolic dysfunction to depressed systolic function"],"prefix":"10.5867","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4706-3821","authenticated-orcid":false,"given":"Alexis","family":"\u00c1lvarez-Aliaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0436-5974","authenticated-orcid":false,"given":"Adonis","family":"Fr\u00f3meta-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7672-5601","authenticated-orcid":false,"given":"Alexis","family":"Su\u00e1rez-Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0104-1715","authenticated-orcid":false,"given":"David","family":"del Llano-Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8818-2704","authenticated-orcid":false,"given":"Joel","family":"Berd\u00fa-Saumell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2933-0663","authenticated-orcid":false,"given":"Yasel Alberto","family":"Lago-Santiesteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3888","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. Gu\u00eda ESC\/ESH 2018 sobre el diagn\u00f3stico y tratamiento de la hipertensi\u00f3n arterial. Rev Esp Cardiol. 2019;72(2): 160.e1-e78.","DOI":"10.1016\/j.recesp.2018.12.005"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012 Jan 26;366(4):321-9. | CrossRef | PubMed |","DOI":"10.1056\/NEJMoa1012848"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"D\u00edez J, Frohlich ED. A translational approach to hypertensive heart disease. Hypertension. 2010;55:1- 8. [Internet] | Link |","DOI":"10.1161\/HYPERTENSIONAHA.109.141887"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"\u00c1lvarez-Aliaga A, Quesada-V\u00e1zquez AJ, Su\u00e1rez-Quesada A, de Llano Sosa D. Design and validation of an Index to predict the development of Hypertensive Cardiopathy. J Cardiol Cardiovasc Med. 2018;(3):008-022. [Internet] | CrossRef |","DOI":"10.29328\/journal.jccm.1001022"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1\u00b725 million people. Lancet. 2014 May 31;383(9932):1899-911. | CrossRef | PubMed |","DOI":"10.1016\/S0140-6736(14)60685-1"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec;42(6):1206-52. | PubMed |","DOI":"10.1161\/01.HYP.0000107251.49515.c2"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63. | PubMed |","DOI":"10.1016\/j.echo.2005.10.005"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006 Mar;7(2):79-108. | PubMed |","DOI":"10.1016\/j.euje.2005.12.014"},{"key":"ref8","unstructured":"P\u00e9rez Caballero MD, Due\u00f1as Herrera A, Alfonso Guerra JP, V\u00e1zquez Vigoa A, Navarro Despaigne D, Hern\u00e1ndez Cueto M, et al. Hipertensi\u00f3n arterial. Gu\u00eda para la prevenci\u00f3n, diagn\u00f3stico y tratamiento. Comisi\u00f3n Nacional T\u00e9cnica Asesora del Programa de Hipertensi\u00f3n Arterial. La Habana: Editorial Ciencias M\u00e9dicas; 2008. [Internet] | Link |"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Zhao W, Hasegawa K, Chen J. The use of food-frequency questionnaires for various purposes in China. Public Health Nutr. 2002 Dec;5(6A):829-33. | PubMed |","DOI":"10.1079\/PHN2002374"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010 May 26;303(20):2043-50. | CrossRef | PubMed |","DOI":"10.1001\/jama.2010.650"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005 Jun;67(6):2089-100. | PubMed |","DOI":"10.1111\/j.1523-1755.2005.00365.x"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003 Nov;26(11):3160-7. | PubMed |","DOI":"10.2337\/diacare.26.11.3160"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Mazumdar M, Glassman JR. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med. 2000 Jan 15;19(1):113-32. | PubMed |","DOI":"10.1002\/(SICI)1097-0258(20000115)19:1<113::AID-SIM245>3.0.CO;2-O"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996 Feb 28;15(4):361-87. | PubMed |","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4"},{"key":"ref15","unstructured":"Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. Springer; 2009:255-79."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"May S, Hosmer DW. Hosmer and Lemeshow type goodness-of-fit statistics for the Cox proportional hazards model. Elsevier; 2004:383-94.","DOI":"10.1016\/S0169-7161(03)23021-2"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Georgiopoulou VV, Kalogeropoulos AP, Raggi P, Butler J. Prevention, diagnosis, and treatment of hypertensive heart disease. Cardiol Clin. 2010 Nov;28(4):675-91. | CrossRef | PubMed |","DOI":"10.1016\/j.ccl.2010.07.005"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Nielsen TL, Plesner LL, Warming PE, Mortensen OH, Iversen KK, Heaf JG. FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction. Nefrologia. 2019 May - Jun;39(3):258-268. | CrossRef | PubMed |","DOI":"10.1016\/j.nefro.2018.10.007"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Schneider MP, Scheppach JB, Raff U, Toncar S, Ritter C, Klink T, et al. Left Ventricular Structure in Patients With Mild-to-Moderate CKD-a Magnetic Resonance Imaging Study. Kidney Int Rep. 2018 Oct 11;4(2):267-274. | CrossRef | PubMed |","DOI":"10.1016\/j.ekir.2018.10.004"},{"key":"ref20","unstructured":"Mart\u00ednez-Castelao A, G\u00f3rriz JL, Segura-de la Morena J, Cebollada J, Escalada J, Esmatjes E, et al. Consensus document for the detection and management of chronic kidney disease. Nefrologia. 2014;34(2):243-62. | CrossRef | PubMed |"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Drawz PE, Alper AB, Anderson AH, Brecklin CS, Charleston J, Chen J, et al. Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage. Clin J Am Soc Nephrol. 2016 Apr 7;11(4):642-52. | CrossRef | PubMed |","DOI":"10.2215\/CJN.08530815"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, et al. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015 Oct 17;386(10003):1588-98. | CrossRef | PubMed |","DOI":"10.1016\/S0140-6736(15)00418-3"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"N\u00fa\u00f1ez J, Mi\u00f1ana G, Santas E, Bertomeu-Gonz\u00e1lez V. Cardiorenal Syndrome in Acute Heart Failure: Revisiting Paradigms. Rev Esp Cardiol (Engl Ed). 2015 May;68(5):426-35. | CrossRef | PubMed |","DOI":"10.1016\/j.rec.2014.10.016"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Tovillas-Mor\u00e1n FJ, Zabaleta-del-Olmo E, Dalf\u00f3-Baqu\u00e9 A, Vilaplana-Cosculluela M, Galcer\u00e1n JM, Coca A. Morbimortalidad cardiovascular y patrones geom\u00e9tricos del ventr\u00edculo izquierdo en pacientes hipertensos atendidos en atenci\u00f3n primaria. Rev Esp Cardiol. 2009; 62:246-54. | CrossRef |","DOI":"10.1016\/S0300-8932(09)70367-7"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018 Aug 7;39(30):2780-2792. | CrossRef | PubMed |","DOI":"10.1093\/eurheartj\/ehy301"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. | CrossRef | PubMed |","DOI":"10.1056\/NEJMoa1504720"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. | CrossRef | PubMed |","DOI":"10.1056\/NEJMoa1611925"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME\u00ae trial. Eur Heart J. 2018 Feb 1;39(5):363-370. | CrossRef | PubMed |","DOI":"10.1093\/eurheartj\/ehx511"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Li J, Kemp BA, Howell NL, Massey J, Mi\u0144czuk K, Huang Q, et al. Metabolic Changes in Spontaneously Hypertensive Rat Hearts Precede Cardiac Dysfunction and Left Ventricular Hypertrophy. J Am Heart Assoc. 2019 Feb 19;8(4):e010926. | CrossRef | PubMed |","DOI":"10.1161\/JAHA.118.010926"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019 Jan;42(Suppl 1):S103-S123. | CrossRef | PubMed |","DOI":"10.2337\/dc19-S010"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. | CrossRef | PubMed |","DOI":"10.1056\/NEJMoa1511939"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Beckett N, Peters R, Leonetti G, Duggan J, Fagard R, Thijs L, et al. Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial. J Hypertens. 2014 Jul;32(7):1478-87; discussion 1487. | CrossRef | PubMed |","DOI":"10.1097\/HJH.0000000000000195"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure--meta-analyses of randomized trials. J Hypertens. 2016 Mar;34(3):373-84; discussion 384. | CrossRef | PubMed |","DOI":"10.1097\/HJH.0000000000000848"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Cuspidi C, Giudici V, Negri F, Meani S, Sala C, Zanchetti A, et al. Improving cardiovascular risk stratification in essential hypertensive patients by indexing left ventricular mass to height(2.7). J Hypertens. 2009 Dec;27(12):2465-71. | CrossRef | PubMed |","DOI":"10.1097\/HJH.0b013e32833105a6"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Gu Q, Dillon CF, Burt VL, Gillum RF. Association of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens. 2010 Jan;23(1):38-45. | CrossRef | PubMed |","DOI":"10.1038\/ajh.2009.191"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Peralta CA, Katz R, Newman AB, Psaty BM, Odden MC. Systolic and diastolic blood pressure, incident cardiovascular events, and death in elderly persons: the role of functional limitation in the Cardiovascular Health Study. Hypertension. 2014 Sep;64(3):472-80. | CrossRef | PubMed |","DOI":"10.1161\/HYPERTENSIONAHA.114.03831"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010 May 26;303(20):2043-50. | CrossRef | PubMed |","DOI":"10.1001\/jama.2010.650"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Maione A, Annemans L, Strippoli G. Proteinuria and clinical outcomes in hypertensive patients. Am J Hypertens. 2009 Nov;22(11):1137-47 | CrossRef |","DOI":"10.1038\/ajh.2009.161"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001 Jul 25;286(4):421-6. | PubMed |","DOI":"10.1001\/jama.286.4.421"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, Weber MA, et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol. 2011 Jul;22(7):1353-64. | CrossRef | PubMed |","DOI":"10.1681\/ASN.2010091001"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Bakris GL, Sarafidis PA, Weir MR, Dahl\u00f6f B, Pitt B, Jamerson K, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 3;375(9721):1173-81. | CrossRef | PubMed |","DOI":"10.1016\/S0140-6736(09)62100-0"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011 Mar 10;364(10):907-17. | CrossRef | PubMed |","DOI":"10.1056\/NEJMoa1007994"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6;367(23):2204-13. | CrossRef | PubMed |","DOI":"10.1056\/NEJMoa1208799"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Zhang Z, Dzau VJ. Angiotensin II type 1 receptor-associated protein is an endogenous inhibitor of angiotensin II type 1 receptor action in cardiac hypertrophy: role in check and balance. Hypertension. 2010 May;55(5):1086-7. | CrossRef | PubMed |","DOI":"10.1161\/HYPERTENSIONAHA.110.150458"},{"key":"ref45","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS. Guia ESC 2016 sobre el diagn\u00f3stico y tratamiento de la insuficiencia cardiaca aguda y cr\u00f3nica. Rev Esp Cardiol. 2016;69(12): 1167.e1-e85. [Internet] | CrossRef |"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Royo-Bordonada M\u00c1, Armario P, Lobos Bejarano JM, Pedro-Botet J, Villar Alvarez F, Elosua R, et al. Adaptaci\u00f3n espa\u00f1ola de las gu\u00edas europeas de 2016 sobre prevenci\u00f3n de la enfermedad cardiovascular en la pr\u00e1ctica cl\u00ednica. Hipertens Riesgo Vasc. 2017;34(1):24-40. [Internet] | CrossRef |","DOI":"10.1016\/j.hipert.2016.11.006"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Jim\u00e9nez F, Cort\u00e9s-Bergoderi M. Update: systemic diseases and the cardiovascular system (i): obesity and the heart. Rev Esp Cardiol. 2011 Feb;64(2):140-9. | CrossRef | PubMed |","DOI":"10.1016\/j.rec.2010.10.011"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Zhang Y, Ren J. Role of cardiac steatosis and lipotoxicity in obesity cardiomyopathy. Hypertension. 2011 Feb;57(2):148-50. | CrossRef | PubMed |","DOI":"10.1161\/HYPERTENSIONAHA.110.164178"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"\u00c1lvarez Aliaga A, Gonz\u00e1lez Aguilera JC, Maceo G\u00f3mez Ldel R. Factors associated to hypertensive heart disease development: a prospective cohort study in Bayamo, Cuba. Medwave. 2016 Jul 7;16(6):e6492. | CrossRef | PubMed |","DOI":"10.5867\/medwave.2016.06.6492"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009 Sep;54(3):475-81. | CrossRef | PubMed |","DOI":"10.1161\/HYPERTENSIONAHA.109.131235"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"L\u00f3pez Salazar B, Ravassa Alb\u00e9niz S, Arias Gued\u00f3n T, Gonz\u00e1lez Miqueo A, Querejeta R, D\u00edez Mart\u00ednez J. [Altered fibrillar collagen metabolism in hypertensive heart failure. Current understanding and future prospects]. Rev Esp Cardiol. 2006 Oct;59(10):1047-57. | PubMed |","DOI":"10.1157\/13093982"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Schulz R, Heusch G. C-reactive protein: just a biomarker of inflammation or a pathophysiological player in myocardial function and morphology? Hypertension. 2011; 57:151-3. [Internet] | Link |","DOI":"10.1161\/HYPERTENSIONAHA.110.165837"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Nagai T, Anzai T, Kaneko H, Mano Y, Anzai A, Maekawa Y, et al. C-reactive protein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response. Hypertension. 2011 Feb;57(2):208-15. | CrossRef | PubMed |","DOI":"10.1161\/HYPERTENSIONAHA.110.158915"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Frohlich ED, Gonz\u00e1lez A, D\u00edez J. Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy. J Hypertens. 2011 Jan;29(1):17-26. | CrossRef | PubMed |","DOI":"10.1097\/HJH.0b013e328340d787"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Downs JR, O'Malley PG. Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med. 2015 Aug 18;163(4):291-7. | CrossRef | PubMed |","DOI":"10.7326\/M15-0840"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 Sep 27;357(13):1301-10. | PubMed |","DOI":"10.1056\/NEJMoa064278"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Ashen MD, Blumenthal RS. Clinical practice. Low HDL cholesterol levels. N Engl J Med. 2005 Sep 22;353(12):1252-60. Review. Erratum in: N Engl J Med. 2006 Jan 12;354(2):215. | PubMed |","DOI":"10.1056\/NEJMcp044370"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Mancia G, Fagard R, Narkiewicz K, Red\u00f3n J, Zanchetti A, B\u00f6hm M, et al. 2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-357. | CrossRef | PubMed |","DOI":"10.1097\/01.hjh.0000431740.32696.cc"},{"key":"ref59","unstructured":"Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF\/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011 May 17;57(20):2037-114. | CrossRef | PubMed |"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Adji A, O'Rourke MF, Namasivayam M. Arterial stiffness, its assessment, prognostic value, and implications for treatment. Am J Hypertens. 2011 Jan;24(1):5-17. | CrossRef | PubMed |","DOI":"10.1038\/ajh.2010.192"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"62. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation. 2009;119:3070-7. [Internet] | Link |","DOI":"10.1161\/CIRCULATIONAHA.108.815944"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008 Mar 27;358(13):1370-80. | CrossRef | PubMed |","DOI":"10.1056\/NEJMra072139"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Gradman AH, Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis. 2006 Mar-Apr;48(5):326-41. | PubMed |","DOI":"10.1016\/j.pcad.2006.02.001"}],"container-title":["Medwave"],"original-title":["Modelo pron\u00f3stico de los cambios evolutivos de la cardiopat\u00eda hipertensiva: desde la disfunci\u00f3n diast\u00f3lica leve hasta la funci\u00f3n sist\u00f3lica deprimida"],"deposited":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T13:52:22Z","timestamp":1591969942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medwave.cl\/link.cgi\/Medwave\/Estudios\/Investigacion\/7873.act"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":64,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2020,4,28]]}},"URL":"https:\/\/doi.org\/10.5867\/medwave.2020.03.7873","relation":{},"ISSN":["0717-6384"],"issn-type":[{"value":"0717-6384","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,28]]}}}